2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 503

Waist Circumference Based Abdominal Obesity Versus Body Mass Index in Rheumatoid Arthritis: Influence on the Risk of Diabetes and Cardiovascular Disease

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 438

What Characterizes Osteoarthritis: Ultrasound-Detected Inflammation but Not Osteophytes Is More Common in Hand Osteoarthritis Than in Painless Bony Enlargements

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 421

What Do Patients with Osteoarthritis Think of Their Preoperative Education before Total Hip Replacement Surgery:Qualitative Study

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 656

What Is the Level of Agreement between Local and Central Readers in the Detection of Active and Structural MRI Lesions Typical of Axial Spondyloarthritis? Data from the Assessments in Spondyloarthritis Classification Cohort Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 76

Whole Blood Targeted Bisulfite Pyrosequencing Identifies Differentially Methylated Regions within Major Histocompatibility Complex (MHC) of Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 228

Widespread Chronic Use of Proton-Pump Inhibitors and Potential for Drug-Drug Interactions in Rheumatoid Arthritis and Lupus Patients

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 753

Young SLE Patients Have Higher Coronary Artery Calcium Scores Compared with Population Controls

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

11:00AM-12:30PM: Abstract Number: 838

Efficacy and Safety of Combined Immunosuppressive Therapy with High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Disease Accompanied By Anti-MDA5-Positive Dermatomyositis -a Multicenter Prospective Study –

3S037 ACR Abstract: Plenary Session I (835–839)

11:00AM-12:30PM: Abstract Number: 837

Efficacy of High-Dose Versus Standard-Dose Influenza Vaccine in Seropositive Rheumatoid Arthritis Patients

3S037 ACR Abstract: Plenary Session I (835–839)

11:00AM-12:30PM: Abstract Number: 839

Fibromyalgia Is Identified in Routine Care on Indices Derived from an MDHAQ (MultiDimensional Health Assessment Questionnaire) with Robust Agreement with 2011 Revised Fibromyalgia Criteria Questionnaire

3S037 ACR Abstract: Plenary Session I (835–839)

11:00AM-12:30PM: Abstract Number: 836

Genetic Risk Score Prediction in Ankylosing Spondylitis

3S037 ACR Abstract: Plenary Session I (835–839)

12:00PM-2:00PM: Abstract Number: PP08

Communication, Support, and Advocacy Lead to Improved Health and Quality of Life

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP09

Improved Quality of Life and Decreased Symptoms of Lupus with Diet, Exercise, and Functional Medicine

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP04

Improved Quality of Life with Patient Engagement in Research

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP05

Integrative Approach to Treatment of an Adult with Juvenile Rheumatoid Arthritis

3S041 ACR/ARHP: Patient Perspectives Poster Session

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].